Randomized Study to Evaluate the Effect of Obicetrapib in Participants With Preclinical Alzheimer's Disease
A Phase 2b, Randomized, Double Blind, Placebo Controlled, Parallel Group Trial to Assess the Efficacy and Safety of Obicetrapib in Participants With Preclinical Alzheimer's Disease (SPINOZA Trial)
- Preclinical Alzheimer's Disease
At a glance
- Phase
- Phase 2
- Study type
- Interventional
- Sponsor
- NewAmsterdam Pharma
- Enrolment target
- 400
- Started
- September 2026
- Main results due
- September 2028
- Study sites
- 1
- Registry updated
- 28 September 2026
Can you take part?
- Ages 55 years to 85 years.
- Open to any sex.
- You need the condition being studied — healthy volunteers are not accepted.
These are the headline rules only. Every study has a longer list, and whether you are eligible is decided by the research team at the site — never by this page.
Read the full eligibility criteria
Inclusion Criteria: * participants with preclinical AD Exclusion Criteria: * APOE genotype not meeting protocol-defined eligibility criteria
What this study is about
In the sponsor’s own words, from the registry.
A study evaluating Obicetrapib in adults potentially at risk for Preclinical Alzheimer's Disease
Study sites(1)
K2 Medical Research
Nashville, Tennessee, United States
Recruiting
Showing 1 of 1 sites. 1 of the 1 site on this study is recruiting right now — a site can stop enrolling while the study as a whole is still open.
Source: ClinicalTrials.gov record NCT07794670. Trialion does not run this study, is not paid to refer anyone to it, and cannot enrol you. Eligibility is always decided by the research team at the site.
Not the right study?
Answer three questions and see the studies recruiting near you, in plain language.
Find a study for me